Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 17, 2022


Dermata Therapeutics, Inc.

(Exact name of registrant as specified in its charter)







(State or Other Jurisdiction

of Incorporation)


(Commission File Number)


(I.R.S. Employer

Identification No.)


3525 Del Mar Heights Rd., #322

San Diego, CA 92130

(Address of principal executive offices, including zip code)



(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class:


Trading Symbol


 Name of Each Exchange on which Registered

Common Stock, par value $0.0001 per share




 The Nasdaq Capital Market

Warrants, exercisable for one share of Common Stock




The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 8.01 (Other Events). 


Dermata Therapeutics, Inc. (the “Company”) recently received a shipment of Spongilla raw material from its exclusive supplier which the Company believes provides sufficient quantities to manufacture enough DMT310 drug product to support the Company’s Phase 3 program in moderate-to-severe acne, a Phase 2 trial in mild-to-moderate psoriasis, and the Company’s nonclinical programs for its DMT310 and DMT410 product candidates. The Company also believes the recent shipment of raw material will be sufficient to complete the manufacturing of registration batches to support the filing of a new drug application for DMT310 for the treatment of moderate-to-severe acne upon the successful completion of the Phase 3 program for that indication.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.









Dated: May 17, 2022


/s/ Gerald T. Proehl




Gerald T. Proehl




Chief Executive Officer